Novartis Pharma AG: Novartis data highlight efficacy of Piqray in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates

Related Keywords

United States , San Antonio , Texas , New Jersey , East Hanover , America , Isabella Zinck , Thomas Hungerbuehler , Ashley Buford , Samir Shah , Julie Masow , Parag Mahanti , Sloan Simpson , Alina Levchuk , Virtual Scientific Program , Twitter , Novartis Oncology Communications , Novartis Us External Communications , Novartis External Communications , Novartis , Exchange Commission , Novartis Pharmaceuticals , Novartis Pharmaceuticals Corporation , Cancer Genome Atlas Network , University Of California San Francisco , Novartis Pharmaceuticals Corp , Helen Diller Family Comprehensive Cancer Center , Antonio Breast Cancer Symposium , Breast Oncology , Clinical Trials Education , California San Francisco , Helen Diller Family Comprehensive Cancer , Scientific Program , Advanced Breast , Safety Informationfrom , San Antonio Breast Cancer Symposium , Cancer Genome Atlas , Aromatase Inhibitor Resistance , Circulating Tumour , Metastatic Breast , Alpelisib Plus Fulvestrant , Participants With , Advanced Breast Cancer After Treatment With , Aromatase Inhibitor , Study Assessing , Subjects With Advanced , Carry Either , Two Part , Placebo Controlled Study , Combination With Trastuzumab , Maintenance Therapy , Patients With , Advanced Breast Cancer With , Alpelisib Plus Olaparib , High Grade Serous Ovarian Cancer , Dharma , Data , Highlight , Efficacy , Piqray , Ther2 , Metastatic , Breast , Dancer , Pik3ca , River , Utation , Mmediately , Most , Cdk4 ,